Compare · MRNA vs VIGL
MRNA vs VIGL
Side-by-side comparison of Moderna Inc. (MRNA) and Vigil Neuroscience Inc. (VIGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and VIGL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $79.63B.
- MRNA has hit the wire 16 times in the past 4 weeks while VIGL has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 11 for VIGL).
- Company
- Moderna Inc.
- Vigil Neuroscience Inc.
- Price
- -
- -
- Market cap
- $79.63B
- -
- 1M return
- -20.24%
- -
- 1Y return
- +710.87%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2022
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 11
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Vigil Neuroscience Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- President Stephen Hoge exercised 152,905 shares at a strike of $12.21, sold $16,900,019 worth of shares (78,375 units at $215.63) as part of a pre-agreed trading plan and gifted 400,000 shares, decreasing direct ownership by 20% to 1,311,095 units (SEC Form 4)
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest VIGL
- SEC Form 15-12G filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Vigil Neuroscience Inc.
- Large owner Atlas Venture Fund Xii, L.P. returned 5,836,874 shares to the company (SEC Form 4)
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.